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Abstract
Phellinus linteus (PL) mushroom possesses anti-tumor property. We previously reported that the treatment with PL caused
cultured human prostate cancer cells to undergo apoptosis. To further studying the mechanisms of PL-mediated apoptosis,
we performed xenograft assay, together with in vitro assays, to evaluate the effect of PL on the genesis and progression of
the tumors formed from the inoculation of prostate cancer PC3 or DU145 cells. After the inoculation, nude mice were
injected with PL every two days for 12 days. Although PL treatment did not prevent the formation of the inoculated tumors,
the growth rate of the tumors after PL treatment was dramatically attenuated. We then tested the effect of PL on the
tumors 12 days after the inoculation. After inoculated tumors reached a certain size, PL was administrated to the mice by
subcutaneous injection. The histochemistry or immunochemistry analysis showed that apoptosis occurred with the
activation of caspase 3 in the tumors formed by inoculating prostate cancer DU145 or PC3 cells. The data was in a good
agreement with that from cultured cells. Thus, our in vivo study suggests that PL not only is able to attenuate tumor
growth, but also to cause tumor regression by inducing apoptosis.
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Introduction
Prostate cancer is a devastated disease in men. Although therapies
(such as surgery or androgen ablation) have improved the survival
rate of the patients, lack of success with hormone-refractory prostate
cancer remains. The advanced tumors are often resistant to
chemotherapeutic drugs. Although the mechanisms for the resistance
are unclear, it has been postulated that the development of tumors,
such as refractory prostate cancer, is related to the accumulation of
genetic or epigenetic alterations. In Asian, PL is one of well-
established medicinal mushrooms that have been using to treat
various human malignancies. Studies showed that the water-soluble
fraction of PL is biologically active, which probably is polysaccharide
[1]–[3]. It has also been shown that PL is able to suppress tumors in
vitro either indirectly by enhancing the host’s immune system, or
directly by inducing apoptosis in tumor cells [4]–[6]. Recently, we
reported that PL is remarkably effective in inhibiting the growth of
various prostate cancer cell lines without toxic effects on normal
prostate epithelial cells [7]. Since PL possesses the anti-tumor, anti-
angiogenic and immunomodulatory properties, it has drawn wide
interests in Asia to develop it for anti-cancer therapeutics. In order to
develop this medicinal mushroom as anti-prostate cancer remedy, a
better understanding of the underlying molecular mechanisms of PL
functions is required.
A potential of a drug to induce apoptosis has been widely used
as a strategy for developing new cancer therapy. It is known that
apoptosis can be triggered by a variety of internal or external
signals. Caspases, a highly conserved family of cysteine proteases,
are key apoptotic effectors in cells and play critical roles in the
regulation of apoptosis through a chain cleavage reaction [8],[9].
Caspases exist as pro-enzymes in the cytosol of cells and are
activated through proteolysis. Upon cell death stimulations,
caspase 8, as an initiator, triggers the activation of downstream
effector caspases 3 and 7, resulting in BID cleavage and
cytochrome c release [10]–[12]. The release of cytochrome c
from the mitochondria to the cytosol causes the formation of the
apoptosome, which in turn triggers the intrinsic apoptotic
machinery. PL has been shown to cause prostate cancer cells to
undergo apoptosis by triggering caspase cascade [6],[7]. Further-
more, low doses of doxorubicin (an anti-cancer drug), together
with low concentrations of PL, have a synergistic effect on the
induction of apoptosis in human prostate cancer cells [13].
Previously, we have reported that PL is able to sensitize cultured
prostate cancer cells to apoptosis, in which caspases were activated
[7]. Our present study, as the continuation of the investigation of
the anti-tumor property of PL, further demonstrated the ability of
PL to induce apoptosis in the tumors by inoculating prostate
cancer DU145 or PC3 cells in nude mice. We showed that the
injection of PL dramatically attenuated the genesis of the tumors
in nude mice after the inoculation. Our study also demonstrated
that upon PL injection, the formed tumors by inoculating DU145




Phellinus Linteus powder was purchased from Panbio-Tech
(Taejon, South Korea) and dissolved in water. After boiled for
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for the study. DMEM (Dulbecco’s modified Eagle’s medium);
antibiotics (penicillin and streptomycin) and trypsin-EDTA were
purchased from Invitrogen. Human prostate cancer PC3 cells
(American Type Culture Collection) were cultured in DMEM
medium supplemented with 10% heat-inactivated fetal calf serum,
2 mM L-glutamine, 100 unites/ml of penicillin, 100 mg/ml of
streptomycin.
Xenograft Assay
Male nude mice (NCRNU-M-M, CrTac: Ncr-Foxn1nu)
(Taconic) at ages of 4–6 weeks were used. Human prostate
cancer PC3 cells (56106) in 100 ml PBS were inoculated into the
right flank area of each mouse. Three mice were served as a
positive control. For the inhibition of tumor formation, 6 mice
were treated with PL (30 mg/kg in 100 ml PBS) right after the
inoculation and subsequently administrated the same amount of
PL every 2 days. Another 3 mice were treated with equal amount
of control Hitachi mushroom solution following the same time
course as that used for PL. The sizes of the tumors were measured
every 4 days with a caliper and calculated according to Tamayko’s
formula [14]. For monitoring tumor regression, after the
implanted tumors reached about 1.0 cm in diameter, the mice
were treated with either PL (30 mg/kg) or the same amount of the
control mushroom solution every 2 days. Ten days later, the mice
were sacrificed and the tumors were isolated for histopathology or
histochemistry analysis.
Histopathology or immunohistochemistry analyses
Isolated tumors were fixed in 4% phosphate-buffered neutral
paraformaldehyde solution (pH 7.4). The histological specimens
were sectioned and stained with hematoxylin/eosin (H&E),
TUNEL or corresponding antibodies (Santa Crutz Biotec.).
Statistic analysis
Means and standard deviations of the results of the experiments
were computed. Standard deviations are displayed as error bars in
the figures. A Student’s T test was used and a p value of ,0.05 was
considered significant.
Results
PL attenuates DU145 or PC3 cells to form tumors in nude
mice
Studies have suggested that PL possess an anti-tumor property
[1],[6],[7]. We demonstrated that PL not only is able to initiate
apoptosis in various malignant prostate cancer cell lines, but
induce G1 arrest in normal prostate epithelial cells [6],[7],[13]. To
further test the anti-tumor effect of PL, xenograft assay was
employed. After inoculated human prostate cancer PC3 cells into
nude mice subcutaneously, PL was simultaneously injected into
the mice. Afterwards, the same amount of PL was injected to the
mice every two days. Twelve days later, the photos of the mice
bearing tumors were taken (Fig. 1A, upper panel) and the slides
mounted with tumor tissues were stained with HE (Fig. 1B, lower
panel). The tumors in PL treated mice were much smaller than
that in the control mice, and showed a distinct pattern of HE
staining.
We also measured the diameters of the inoculated tumors, one
week later after the inoculation when all the mice started to show
the sign of the formation of solid tumor masses. The measurements
were taken every four days for 12 days (Fig. 1B and C). At day
12, the control tumor messes from the inoculation of two cell lines
were about more than 2 folds bigger than those treated by PL. To
exclude the possibility of toxicity rendered by PL, the weight
(Fig. 2A) and water consumption (Fig. 2B) of the mice were
measured and compared. The PL-treated mice had a similar
weight or water consumption as the controls, suggesting that PL
did not have a side-effect on treated or untreated mice. To further
determine whether PL treatment had any toxic effects on the mice,
the livers were also isolated out from the animals. The
histochemistry staining with HE dye showed that the structures
of liver from PL-treated mice were similar as that isolated from the
control mice (data not shown). Both livers appeared healthy
without any evidence of degeneration, fibrosis, apoptosis or
necrosis. The in vivo study suggests that PL is able to attenuate
the speed of the growth of the inoculated tumors in nude mice.
PL treatment causes the growth regression in the tumors
inoculated by prostate cancer cells
We then tested the effect of PL on the existing tumors. When
the inoculated tumors reached to the size of 1.0 cm in diameter,
PL was injected into the mice every two days for total ten days.
The tumors were isolated and prepared for histopathological or
immunohistochemitry analysis. The HE staining revealed that the
tumors isolated from PL- or control mouse were well-circum-
scribed with connective tissues (Fig. 3A). Cell death appeared to
occur in PL-treated tumors from the inoculation of two different
prostate cancer cell lines with many unstained vacuoles, which was
absent in the control tumors. To further determine whether
apoptosis occurs in PL-treated tumors, immunohistochemistry
analysis using TNUEL staining (to detect DNA strand breaks) was
performed (Fig. 3B). The slides from PL-treated tumors were
strongly stained with TUNEL staining, but only a few TUNEL
staining positive cells were detected in control tumors. The
percentages of the cells stained TUNEL positively was measured
in the control and PL-treated tumors (data not shown). More than
30% of cells in PL-treated tumor had broken DNA strand and
very small percent of cells from the control tumors (about 5%)
stained positively. The immunohistochemistry staining using anti-
caspase 3 antibody was also performed to detect the expression of
caspase 3 (Fig. 3C). Large numbers of the cells in PL-treated
tumor formed by the inoculation of PC3 cells were reacted with
the antibody. In comparison, only a few cells in the control tumor
expressed a high level of caspase 3. Similar results were obtained
from the tumors formed by the inoculation of DU145 cells (data
not shown). Thus, the results indicate that cell death occurred in
PL-treated tumor is through apoptosis.
To further test the ability of PL to induce apoptosis, DU145 and
PC3 cells were treated with PL at 1 mg/ml or 2 mg/ml for 48 h.
Annexin V analysis were conducted (Fig. 4). After being treated
with PL, about 15% of PL-treated cells underwent apoptosis, in a
dose-dependent fashion. A baseline staining of Annexin V was
seen in the control tumors. Interestingly, PC3 cells were more
sensitive to PL than DU145 cells. Overall, the in vitro data is
consistent with that obtained from the animal experiments.
Discussion
Previously, we demonstrated that PL induces cultured prostate
cancer cells to undergo apoptosis [7],[13]. Here, using xenograft
assay, we showed that PL is capable of eliciting an apoptotic
response in vivo to block the growth of the tumors formed by the
inoculation of human prostate cancer DU145 or PC3 cells. The
histochemistry staining analysis showed that the majority of the
cells in the tumors isolated from PL-treated mice are apoptotic,
manifested by positively stained with TUNEL and reacted with an
anti-caspase 3 antibody. The occurrence of apoptosis was also
Apoptosis by Phellinus Linteus
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with PL for 48 in a dose dependent manner. Thus, our study,
using in vivo as well in vitro assays, inidcates that PL treatment
initiates caspase cascade to induce apoptosis in prostate cancer
cells, which provide a strong evidence for the potential of PL as an
anti-prostate cancer remedy.
Figure 1. Attenuation of the tumors formed by the inoculation of DU145 or PC3 cells into nude mice after the treatment with PL. A.
DU145 or PC3 cells were inoculated subcutaneously into nude mice. Twelve days later, the photos of the mice bearing the inoculated tumors were
taken (upper panel). The tumors were isolated from PL treated or control mice. The slides mounted with the tumor tissues were prepared and stained
with HE dye (lower panel). B and C. A group of 6 mice were injected with PL (30 mg/kg) in water from day 0 and subsequently administrated every 2
days. Another group of 3 was as the controls. One week later when the inoculated tumor started to form, the sizes of the tumors were measured
every 4 days.
doi:10.1371/journal.pone.0009885.g001
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9885Figure 2. Analysis of side-effects of PL. A and B. After the tumor nodules were formed, the body weight (A) and water consumption (B) of each
mouse with or without treated with PL were measured. Error bars represent the standard deviation from 3–6 mice.
doi:10.1371/journal.pone.0009885.g002
Figure 3. Histopathology or immunohistochemistry staining of PL-treated or control tumors isolated from the mice. A. The tumors
were prepared for hematoxylin and eosin staining. B and C. The slides mounted with the tumor tissues were stained with TUNEL agent (B) or anti-
caspase 3 antibody (C).
doi:10.1371/journal.pone.0009885.g003
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reported that PL, at high doses, induces control lung epithelial cells
to arrest in the G1 phase of the cell cycle by blocking the
expression of cyclin D1 and its interaction with cell cycle-
dependent kinases 4 and 6 [6]. In our current study, the data
from histopathological analysis demonstrate that the injection of
PL into nude mice inoculated with either DU145 or PC3 prostate
cancer cells has no toxic effect on the mice, manifested by that the
treatment plays no role in the growth or water consumption of the
mice. Importantly, the liver samples from the treated mice are
normal without degeneration or fibrosis. It is possible that, like in
vitro experiments, treatment with PL elicits cell checkpoint controls
in normal tissues or organs, which is not harmful to the mice. In
the inoculated tumors, the same treatment appears to be very
much cytotoxic.
Programmed cell death is important machinery for excluding
abnormal or cancerous cells. Activation of caspase family members is
at the core of apoptosis, representing a point of intersection of various
apoptotic pathways in various types of cancer cells, including prostate
cancer cells. TNF or Fas/CD95 receptors, mitochondrial proteins
(such as cytochrome c) and granzyme are able to induce cell death
through activation of the caspase cascade [8],[9]. Damage to or stress
i nt h eE Ro rG o l g ih a sb e e ns h o w nt ob ea b l et ot r i g g e ra p o p t o s i s
[15],[16]. Studies have shown that the unfolded protein response or
lack of calcium is responsible for ER-mediated apoptosis [15]. ER
stress has been demonstrated to cause the translocation of certain
caspases to the ER or Golgi and the execution of apoptosis there.
Calcium released from the ER during times of ATP deficiency is an
important element in apoptosis induced by ischemia-reperfusion
injury. We have shown that PL treatment triggers caspase activation
in cultured prostate cancer cells [7],[13]. Our in vivo study indicates
that PL treatment is also able to initiate apoptosis via activating
caspase 3 that are the effector in caspase chain reaction. The
investigation of whether other caspases are involved in the induction
of apoptosis in vivo is under way.
PL is one of well-established medicinal mushrooms that have been
takenorallyasacommonhealth-promotingdietarysupplementoran
adjuvant to treat malignancies in Asia for many decades. The
extraction from water-soluble PL fraction shows a relatively
homogeneous molecular weight distribution on gel permeation
HPLC and is estimated to be around 150–180 kD from the retention
time on HPLC pullulan molecular markers [1]. The main
components of PL have been suggested to be various polysaccharides
[1]–[3]. It has also been shown that the water soluble fraction of PL is
able to suppress tumors either indirectly by enhancing the host’s
immune system, or directly by inducing apoptosis in tumor cells
[4],[5]. However, it is still unclear which compositions of polysac-
charide in PL possess the anti-cancer effect.
In summary, the successful use of PL to treat prostate cancer
requires the fully understanding of the mechanisms for how PL
mediates anti-tumor activities in tumors. Our previous study
demonstrated that PL, through activation of caspases, is able to
induce apoptosis in cultured cancer cells. In the present investigation,
using xenograftassay, we further demonstrate that the injection of PL
into nude mice with formed subcutaneous tumors by inoculated with
prostate cancer DU145 or PC3 cells induces majority of inoculated
tumor cells to lose their viabilities. Thus, our in vivo data support the
notion that PL, by switching on a tumor suppression-related
machinery, can be developed as an efficient therapy to treat human
malignancies, such as refractory prostate cancer.
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Figure 4. Induction of apoptosis in cultured DU145 and PC3 cells in response to PL treatment. The cells were treated with 1 mg/ml or
2 mg/ml for 48 h, and subsequently stained with Annexin V. Error bars represent the standard deviation from 3 independent experiments.
doi:10.1371/journal.pone.0009885.g004
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